Association between the C3435T polymorphism of ABCB1/MDR1 gene (rs1045642) and colorectal cancer susceptibility: A meta-analysis based on 11,339 subjects

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1949-1957

  Zhao, Li ^a   Li, Kai ^a   Li, Wusheng ^a   Yang, Zhen ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

ATP binding cassette B1; Colorectal cancer; Meta analysis; Multidrug resistance 1 gene; Polymorphism

Indexed keywords

CYTOSINE; MULTIDRUG RESISTANCE PROTEIN 1; THYMINE;

ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); MULTIDRUG RESISTANCE 1 GENE; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

EID: 84878686173     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0740-0     Document Type: Article

References (31)

1. Lee JJ, Chu E. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer. Clin Colorectal Cancer. 2007;7:16-20.
2. Huxley RR, Ansary-Moghaddam A, Clifton P. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 2009;125:71-80.
3. Bodor M, Kelly EJ, Ho RJ. Characterization of the human MDR1 gene. AAPS J. 2005;7(1):E1-5.
4. Allikmets R, Gerrard B, Hutchinson A, Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet. 1996;5(10):1649-55.
5. Yamada O, Ozaki K, Furukawa T, Machida M, Wang YH, Motoji T, et al. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1. Cell Signal. 2011;23(7):1119-27.
6. Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets. 2005;5:457-68.
7. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein. Trends Biochem Sci. 2000;25(1):1-6.
8. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-8.
9. Drozdzik M, Mysliwiec K, Lewinska-Chelstowska M, Banach J, Drozdzik A, Grabarek J. P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. J Clin Periodontol. 2004;31:758-63.
10. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
12. Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Bialecka M, Gornik W, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol. 2005;61:389-94.
13. Lee BI, Choi KY, Lee KM, Chung WC, Kim BW, et al. Is C3435T polymorphism of MDR1 related to inflammatory bowel disease or colorectal cancer in Korean? Korean J Gastroenterol. 2006;47:22-9.
14. Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, et al. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet. 2006;21:126-32.
15. Bae SY, Choi SK, Kim KR, Park CS, Lee SK, et al. Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci. 2006;97:774-9.
16. Osswald E, Johne A, Laschinski G, Arjomand-Nahad F, Malzahn U, et al. Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol. 2007;63:9-16.
17. Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, et al. No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol. 2008;134:317-22.
18. Potocnik U, Glavac D, Dean M. Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet Cytogenet. 2008;183:28-34.
19. Andersen V, Stergaard M, Christensen J, et al. Polymorphisms in the xenobiotic transporter Multidrug Resistance1(MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009;9:1-11.
20. Panczyk M, Balcerczak E, Piaskowski S, et al. ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. Int J Colorectal Dis. 2009;24:895-905.
21. Khedri A, Nejat-Shokouhi A, Salek R, et al. Association of the colorectal cancer and MDR1 gene polymorphism in an Iranian population. Mol Biol Rep. 2011;38:2939-43.
22. Sainz J, Rudolph A, Hein R, et al. Association of genetic polymorphisms in ESR2, HSD17B1, ABCB1, and SHBG genes with colorectal cancer risk. Endocr Relat Cancer. 2011;18:265-76.
23. Campa D, Sainz J, Pardini B, Vodickova L, Naccarati A, et al. A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer. PLoS One. 2012;7(3):e32784.
24. Ozhan G, Kara M, Sari FM, Yanar HT, Ercan G, et al. Associations between the functional polymorphisms in the ABCB1 transporter gene and colorectal cancer risk: a case-control study in Turkish population. Toxicol Mech Methods. 2013;15:1-5.
25. Petrova DT, Nedeva P, Maslyankov S, et al. No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol. 2008;134:317-22.
26. Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 2010;10:62-9.
27. George J, Dharanipragada K, Krishnamachari S, Chandrasekaran A, Sam SS, et al. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer. 2009;9:161-5.
28. Chen S, Huo X, Lin Y, Ban H, Li W, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health. 2010;213:140-5.
29. Paule B, Castagne V, Picard V, Saffroy R, Adam R, et al. MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med Oncol. 2010;27:1066-72.
30. Krupoves A, Seidman EG, Mack D, Israel D, Morgan K, et al. Associations between ABCB1/MDR1 gene polymorphisms and Crohn's disease: a gene-wide study in a pediatric population. Inflamm Bowel Dis. 2009;15:900-8.
31. Fujisawa T, Ikegami H, Kawaguchi Y, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia. 1998;41(1):47-53.